Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 1/20 | 0.62 |
| ▸ | CTSL | P07711 | 4/20 | 0.58 |
| ▸ | CTSS | P25774 | 4/20 | 0.58 |
| ▸ | CTSK | P43235 | 4/20 | 0.58 |
| ▸ | CTSV | O60911 | 2/20 | 0.58 |
| ▸ | PLAT | P00750 | 2/20 | 0.58 |
| ▸ | CTSH | P09668 | 2/20 | 0.58 |
| ▸ | CASP14 | P31944 | 2/20 | 0.58 |
| ▸ | CASP6 | P55212 | 2/20 | 0.58 |
| ▸ | CTSZ | Q9UBR2 | 2/20 | 0.58 |
| ▸ | CTSB | P07858 | 3/20 | 0.57 |
| ▸ | CASP4 | P49662 | 1/20 | 0.53 |
| ▸ | CASP5 | P51878 | 1/20 | 0.53 |
| ▸ | PDE4A | P27815 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3346602 | 0.85 | CTSV (0.70) | RAB9ACTSLCTSSCTSKCTSV | |
| SCHEMBL14600703 | 0.84 | RAB9A (0.75) | RAB9ACTSLCTSSCTSKCTSV | |
| SCHEMBL13326008 | 0.84 | RAB9A (0.75) | RAB9ACTSLCTSSCTSKCTSV | |
| SCHEMBL20938665 | 0.84 | RAB9A (0.75) | RAB9ACTSLCTSSCTSKCTSV | |
| SCHEMBL13326014 | 0.82 | GALR2 (0.67) | RAB9ACTSLCTSSCTSKCTSV | |
| SCHEMBL2874930 | 0.81 | NFKB1 (0.65) | RAB9A | |
| SCHEMBL14294391 | 0.81 | RAB9A (0.62) | RAB9ACTSLCTSSCTSKCTSV | |
| SCHEMBL5029172 | 0.81 | RAB9A (0.70) | RAB9ACTSLCTSSCTSKCTSV | |
| SCHEMBL5032293 | 0.80 | CTSL (0.76) | RAB9ACTSLCTSSCTSKCTSV | |
| SCHEMBL8524478 | 0.80 | MEN1 (0.71) | RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7335770-B2 | Triazine compounds and their analogs, compositions, and methods | REDDY U5 THERAPEUTICS, INC. (US) | 2008-02-26 | — | — | US | disclosed |
| US-7335770-B2 | Triazine compounds and their analogs, compositions, and methods | REDDY U5 THERAPEUTICS, INC. (US) | 2008-02-26 | — | — | US | disclosed |
| US-7335770-B2 | Triazine compounds and their analogs, compositions, and methods | REDDY U5 THERAPEUTICS, INC. (US) | 2008-02-26 | — | — | US | disclosed |
| US-20050227983-A1 | Triazine compounds and their analogs, compositions, and methods | DR. REDDY'S LABORATORIES LTD. (IN) | 2005-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050227983-A1 | Triazine compounds and their analogs, compositions, and methods | MYLK, SMAD3, GID4 | RAB9A 3708/4885CTSL 3954/4885CTSS 3208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.